US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Affimed N.V. - Common Stock (NQ:AFMD)

0.1815 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Affimed N.V. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
From Affimed N.V.
Via GlobeNewswire
News headline image
Earnings Preview For Affimed ↗
 
Via Benzinga
Analyst Ratings for Affimed ↗
 
Via Benzinga
News headline image
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Reports 2022 Financial Results and Operational Progress
From Affimed N.V.
Via GlobeNewswire
4 Analysts Have This to Say About Affimed ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 23, 2023 ↗
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for
From Affimed N.V.
Via GlobeNewswire
News headline image
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
From Affimed N.V.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
News headline image
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
From Affimed N.V.
Via GlobeNewswire
News headline image
Dow Surges Over 250 Points; Weber Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 250 points on Monday 
Via Benzinga
News headline image
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. 
Via Benzinga
News headline image
Analyst Says Affimed's 'Innate Cell Engagers Like No Others,' Sees Mammoth Upside ↗
H.C. Wainwright initiated coverage on Affimed NV (NASDAQ: AFMD), a clinical-stage biotechnology company focused on developing innate cell engagers (ICEs) for cancer treatment.  
Via Benzinga
News headline image
Crude Oil Rises Sharply; Adicet Bio Shares Plunge ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Monday 
Via Benzinga
News headline image
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH
From Affimed N.V.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 ↗
 
Via Benzinga
News headline image
US Stocks Higher; Dow Rises Over 100 Points ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Monday 
Via Benzinga
News headline image
Citing Lack Of Durability, Affimed Scraps AFM13 Monotherapy Plans For NK Cell Combo ↗
 
Via Benzinga
News headline image
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
From Affimed N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >